Navigation Links
Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers

TARRYTOWN, N.Y., Jan. 23 /PRNewswire/ -- Aerolase Corporation, a leading manufacturer of next-generation portable lasers for aesthetic skin treatments, today announced that sales increased dramatically in 2008 over 2007. The company's unique product offerings in the aesthetic laser market helped to more than offset current economic conditions, according to Aerolase executives.

"December 2008 was a record sales month for Aerolase, and 2008 overall represented strong revenue growth with continued gains in Aerolase brand equity," said Dr. Pavel Efremkin, CEO. The company also reported that Q4 2008 revenues increased 119% compared with the corresponding period in 2007, and full-year 2008 revenues increased 76% vs. 2007.

"We are specifically pleased with increased popularity of our leading laser products -- LightPod Neo(TM) and LightPod Era(TM) which perform the full range of popular aesthetic laser skin treatments, including pain-free hair removal, facial skin rejuvenation, skin tightening, spider veins and other vascular lesion removal, scar reduction, treatment of pigmented lesions, acne clearance, tattoo reduction and many others."

In addition, the ASP (average selling price per laser) for LightPod lasers in 2008 increased 14% vs. 2007. "There is a clear and powerful trend of Primary Care Physicians (PCPs) actively adding medical aesthetic treatments to the scope of their regular medical practices," he said. "This trend is based on the increasing demand for rejuvenation from the aging population, who now actively seek these services from their trusted medical providers. The resulting new cash income is highly attractive for these PCPs whose economic circumstances continue to erode, thanks especially to declining reimbursement rates from medical insurers."

Sales to PCPs fueled the growth of Aerolase in 2008, with over half of its sales going into this market segment. The core segment of dermatologists and plastic surgeons is still active for Aerolase, representing about one third of revenues.

"The segment of over 300,000 U.S. PCPs is a huge market opportunity for Aerolase," says Mitchell S. Stern, managing director of SMH Capital Inc., a subsidiary of Sanders Morris Harris Group (Symbol SMHG), which is a financial adviser to Aerolase. "As so many PCPs are just starting medical aesthetic practices, the Nd:YAG 1064nm laser is a natural first choice as it is a must-have laser modality for any aesthetic practitioner -- and the LightPod Neo is clearly the best YAG laser available for this market segment due to its unique combination of high efficacy, exceptional versatility and safety, and a very affordable price. We are very pleased to have Aerolase as our client as it is not easy to find a high growth, high margin company in today's challenging environment," Stern said.

About Aerolase

Aerolase Corporation, Tarrytown, NY, is a world leader in the miniaturization of high-powered medical lasers. This core technology has been commercialized in the fields of medical & aesthetic dermatology as well as capillary blood testing and diabetes management. The company's LightPod(R) lasers cover most aesthetic laser procedures on all skin types as well as many medical treatments. Aerolase lasers are packaged in the innovative LightPod system which utilizes air, rather than water, to continuously cool the internal laser emitter; this patented breakthrough resulted in a laser system that is portable and maintenance-free, also inherently less costly to manufacture and therefore more affordable. For more information, visit

About SMH Capital Inc.

SMH Capital is a registered broker-dealer and a subsidiary of Sanders Morris Harris Group (Nasdaq: SMHG) (member FINRA/SIPC). Sanders Morris Harris Group is a financial services holding company headquartered in Houston that manages approximately $10.3 billion in client assets. The subsidiaries and affiliates of Sanders Morris Harris Group deliver superior wealth advisory, asset management, and capital markets services to individual and institutional investors and middle-market companies. Its operating entities are Dickenson Group, Edelman Financial Center, Salient Partners, Salient Trust Co. LTA, SMH Capital, SMH Capital Advisors, Select Sports Group, and The Rikoon Group. Sanders Morris Harris Group has over 600 employees in 21 states. Additional information is available at

SOURCE Aerolase Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Aerolase Retains SMH Capital Inc. to Advise on Corporate Expansion
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):